Hematologic Diseases Clinical Trial
— NSFMOfficial title:
Evaluation of the Impact of the Use of the Digital Solution NewSpringForMe on Transplanted Patients' Quality of Life and Support (Bone Marrow or Peripheral Stem Cells Allotransplantation)
Bone marrow transplantation is both a great treatment for patients with hematological diseases. It is also one of the only hopes of staying alive by "starting from scratch". It is a trying life experience, at all its stages. To support these patients and increase their success in healing and returning to a "normal life", quality of life is an ally of choice for the success of care. NewSpringForMe is an innovative tool designed for the benefit of transplant patients, through the deployment of unprecedented interdisciplinary support benefiting from the best digital technologies. This digital solution is aimed at all patients, adults and pediatrics, before, during and after bone marrow transplantation, in a long-term approach. NewSpringForMe results from the multidisciplinary collaboration of medical and paramedical experts in the field of hematology and transplantation, as well as in the field of psychology. With NewSpringForMe, each transplant patient has a personalized and scalable space accessible via a web platform, constantly offering, according to their needs and at their own pace, a range of recommendations, tools and exercises in psychology, nutrition / dietetics and physical activity, the three pillars of overall well-being. Perfectly integrated into the care pathway and the transplant protocol, from the announcement of the treatment to the long-term follow-up, several years after the intervention, NewSpringForMe complements the medical treatments provided by the medical profession: the communication of the assessments from the platform as well as patient data for caregivers allows adaptation of therapies and optimization of medical care. Thanks to the consideration of individual parameters and their evolution, and thanks to specific algorithms, each tool is adapted to the course of care and to the life of each patient, as well as to their personal health situation throughout their transplant journey. In order to demonstrate the benefits of using NewSpringForMe, the project plans to evaluate the platform and its impact on the quality of life in patients with hematological diseases. This evaluation will be done by the patients themselves and by the nursing staff. The evaluation will be carried out using a monocentric approach on a pilot cohort. The objective is to demonstrate that integrative health ensuring simultaneous care of body and mind increases the chances of success of the transplant while limiting post-transplant complications.
Status | Recruiting |
Enrollment | 170 |
Est. completion date | December 31, 2024 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria : - at least 18 years old - with a first indication for allograft bone marrow or Peripheric Stem Cells - monitored by the adult hematology transplant department St-Louis Hospital - having signed the consent - affiliated to a social security scheme - able to understand the objectives of the study and to use a digital tool Exclusion criteria : - aged under 18 - with an indication of second or third allograft - not being affiliated to a social security scheme |
Country | Name | City | State |
---|---|---|---|
France | Service Hématologie Greffe Trèfle 3, Hôpital Saint-Louis, AP-HP | Paris |
Lead Sponsor | Collaborator |
---|---|
Fonds de Dotation HTC Project | Association Aïda, Association Laurette Fugain, Clinicprosport, ELLYE, Fondation AFNIC, Fondation du LEEM, Gilead Sciences, Groupe Apicil, LAPSCO, Université Clermont-Auvergne, Novartis Pharmaceuticals, Nutricia Nutrition Clinique, Pfizer, Pierre Fabre Medicament, Saint-Louis Hospital, Paris, France, University Hospital, Clermont-Ferrand |
France,
Brotelle T, Lemal R, Cabrespine A, Combal C, Hermet E, Ravinet A, Bay JO, Bouteloup C. Prevalence of malnutrition in adult patients previously treated with allogeneic hematopoietic stem-cell transplantation. Clin Nutr. 2018 Apr;37(2):739-745. doi: 10.1016/j.clnu.2017.03.016. Epub 2017 Mar 28. — View Citation
Corman M, Rubio MT, Cabrespine A, Brindel I, Bay JO, Peffault De La Tour R, Dambrun M. Mental health and quality of life of patients undergoing hematopoietic stem cell transplantation (HSCT) prior to hospitalization: a cross-sectional complete state health study. Health Psychol Behav Med. 2021 Jan 28;9(1):70-83. doi: 10.1080/21642850.2021.1873140. — View Citation
Dirou S, Chambellan A, Chevallier P, Germaud P, Lamirault G, Gourraud PA, Perrot B, Delasalle B, Forestier B, Guillaume T, Peterlin P, Garnier A, Magnan A, Blanc FX, Lemarchand P. Deconditioning, fatigue and impaired quality of life in long-term survivors after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018 Mar;53(3):281-290. doi: 10.1038/s41409-017-0057-5. Epub 2017 Dec 21. — View Citation
Hoodin F, Uberti JP, Lynch TJ, Steele P, Ratanatharathorn V. Do negative or positive emotions differentially impact mortality after adult stem cell transplant? Bone Marrow Transplant. 2006 Aug;38(4):255-64. doi: 10.1038/sj.bmt.1705419. Epub 2006 Jun 19. — View Citation
Kisch A, Lenhoff S, Zdravkovic S, Bolmsjo I. Factors associated with changes in quality of life in patients undergoing allogeneic haematopoietic stem cell transplantation. Eur J Cancer Care (Engl). 2012 Nov;21(6):735-46. doi: 10.1111/j.1365-2354.2012.01354.x. Epub 2012 Apr 23. — View Citation
Snowden JA, Sanchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, Dolstra H, Duarte RF, Glass B, Greco R, Lankester AC, Mohty M, Neven B, de Latour RP, Pedrazzoli P, Peric Z, Yakoub-Agha I, Sureda A, Kroger N; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022 Aug;57(8):1217-1239. doi: 10.1038/s41409-022-01691-w. Epub 2022 May 19. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Negative affects | Level of negative affect (PHQ, Patient Health Questionnaire, Spitzer et al., 2006). Scales measuring sad mood in 9 items (from 0 "never" to 3 "almost every day") and anxious mood in 7 items (from 0 "never" to 3 "almost every day").
Simple Verbal Scale (EVS) for assessing pain intensity (from 0 "no pain" to 10 "maximum pain imaginable"). Data will be collected at each connection and each time the platform and spaces are used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment. |
12 months | |
Primary | Positive affects | Level of positive affects (SA-DHS, Subjective Authentic Durable Happiness Scale, Dambrun et al., 2012). Scale of 13 items (from 1 "very low" to 7 "very high") measuring the level of well-being.
Data will be collected at each connection and each time the platform and spaces are used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment. |
12 months | |
Primary | Life quality | Quality of life (SF-12, Gandek, Ware & Aronson, 1998)
Data will be collected at each connection and each time the platform and spaces are used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment. |
12 months | |
Primary | Life values | Identification of life values (Valued Living Questionnaire, Wilson & Groom, 2002). 10-item scale (from 1 "not at all important" to 10 "very important").
Data will be collected at each connection and each time the platform and spaces are used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment. |
12 months | |
Primary | Mindfulness | Level of dispositional mindfulness (FFMQ-15, 15 item Five Facets Mindfulness Questionnaire, Baer et al., 2008; Gu et al., 2016) in 15 items (from 1 "never true" to 5 "always true")
Data will be collected at each connection and each time the platform and spaces are used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment. |
12 months | |
Primary | Pain intensity | Simple Verbal Scale (EVS) for assessing pain intensity (from 0 "no pain" to 10 "maximum pain imaginable")
Data will be collected at each connection and each time the platform and spaces used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment. |
12 months | |
Primary | Physical effort | Stress test: TM6 walking test (distance in meters measured for 6 minutes)
Data will be collected at each connection and each time the platform and spaces are used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment. |
12 months | |
Primary | Physical suppleness | Shoulder flexibility test and lower limb spine test (in centimeters). For the shoulder test, the distance is calculated between the two hands located behind the back of the individual performing the test. For the lower limb spine test, the distance measured is the finger-to-ground distance.
Data will be collected at each connection and each time the platform and spaces are used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment. |
12 months | |
Primary | Physical activity level | Level of physical activity using a specific self-assessment questionnaire (see J. Ricci and L. Gagnon, University of Montreal, modified by F. Laureyns and JM. Séné) to measure physical activity and determine a profile (inactive, active, very active) depending on the score (ranging from 0 to 5).
Data will be collected at each connection and each time the platform and spaces are used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment. |
12 months | |
Primary | Fatigue | Fatigue assessed by the Pichot scale (see "Scales and assessment tools in general medicine" J. Gardenas et Coll. -Le Généraliste- Supplement to No. 2187; March 2002). This scale allows you to calculate the level of fatigue (from 0 not at all to 4 extremely). It includes 8 items: "I lack energy", "everything requires effort", "I feel weak in certain parts of the body", "my arms or legs are heavy", "I feel tired without reason", "I want to lie down to rest", "I have difficulty concentrating", "I feel tired, heavy and stiff".
Data will be collected at each connection and each time the platform and spaces are used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment. |
12 months | |
Primary | Body mass index | Function of the weight in kg and the height in m
Data will be collected at each connection and each time the platform and spaces are used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment. |
12 months | |
Primary | Appetite quality | Using a scale
Data will be collected at each connection and each time the platform and spaces are used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment |
12 months | |
Primary | Ingested quantities | Food intake using the food intake assessment tool (EPA).
Data will be collected at each connection and each time the platform and spaces are used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment. |
12 months | |
Primary | Eating disorders | Occurrence of eating disorders such as nausea, vomiting, inappetence, dysgesia, dysphagia
Data will be collected at each connection and each time the platform and spaces are used. However, a connection to the platform and to the psychology, nutrition and physical activity spaces will be required at times defined as follows, in order to allow data collection on basic times applicable to all patients and to allow a relevant assessment. |
12 months | |
Primary | Occurrence and extent of post-transplant complications and post-transplant recovery | Nature, frequency of occurrence and extent of post-transplant complications.
Number of therapeutic protocols initiated to treat complications These data relating to post-transplant complications will not be collected from the NewSpringForMe platform but collected from the patient's medical file by the team caregiver. All these outcomes will be aggregated to achieve a final score related to the post-transplant complications |
12 months | |
Primary | Occurrence of hospitalizations | - Average cumulative duration (in days) of unscheduled hospitalizations
These data relating to post-transplant complications will not be collected from the NewSpringForMe platform but collected from the patient's medical file by the team caregiver. |
12 months | |
Primary | Post-transplant recovery | Overall survival
Occurrence of relapse Recovery These data relating to post-transplant complications will not be collected from the NewSpringForMe platform but collected from the patient's medical file by the team caregiver. They will be aggregated to arrive to a final score combining their values. |
12 months | |
Secondary | Admissibility of NewSpringForMe and its tools in terms of attractiveness, understanding, usefulness and relevance | Number of connections to the platform
Overall duration of use of the platform and by space Perceived ease of use (e.g. accessibility, ergonomics), perceived usefulness, positive and negative attitude towards the tool (appreciation of content, functionality), intention to use All these outcomes will be assessed by scales that share common unit measure. They will be aggregated to achieve a radar graph. |
12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04094844 -
Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation
|
N/A | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Recruiting |
NCT03918343 -
Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
|
N/A | |
Completed |
NCT01445561 -
Ultra Low Dose Interleukin-2 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04168983 -
Impact of Sophrology on the Pain Felt During a Bone Marrow Aspiration and Biopsy
|
N/A | |
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Completed |
NCT01108159 -
Integrated Whole-Genome Analysis of Hematologic Disorders
|
||
Completed |
NCT00800839 -
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
|
Phase 2 | |
Completed |
NCT00213239 -
A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children
|
Phase 1/Phase 2 | |
Terminated |
NCT00208949 -
A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF
|
Phase 2 | |
Terminated |
NCT00176826 -
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
|
Phase 2/Phase 3 | |
Completed |
NCT00208962 -
Allogeneic Cell Therapy for Adults With Hematologic Malignancies
|
Phase 2 | |
Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
Completed |
NCT00000587 -
Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection
|
Phase 2 | |
Active, not recruiting |
NCT03655678 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia
|
Phase 2/Phase 3 | |
Recruiting |
NCT05487794 -
Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men With Erythrocytosis
|
N/A | |
Completed |
NCT03611257 -
Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases
|
N/A | |
Completed |
NCT02827149 -
High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT
|
||
Completed |
NCT04584528 -
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
|
N/A |